Introduction: During recent years, therapy in chronic lymphocytic leukemia (CLL) has
changed dramatically. The introduction of small molecule inhibitors has shown remarkable …

Simple Summary Targeted agents, such as Bruton's Tyrosine Kinase inhibitors and BCL-2
inhibitors, have transformed the treatment landscape for Chronic Lymphocytic Leukemia …

The therapeutic landscape for chronic lymphocytic leukemia (CLL) has dramatically
changed during the past ten years with the shift from conventional chemo-immunotherapy …

Introduction Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),
characterized by its monoclonal lymphoproliferative nature, is an indolent but incurable …

Several novel treatments for chronic lymphocytic leukemia (CLL) have been recently
approved based on the results of randomized clinical trials. However, real-world evidence …

Background The treatment landscape for chronic lymphocytic leukemia (CLL) continues to
undergo considerable evolution. Optimal selection of initial therapy from multiple effective …

Introduction: In recent years, innovative mechanism-based drugs have enriched the
therapeutic armamentarium for patients with chronic lymphocytic leukemia (CLL) and are …

Introduction This study assessed treatment discontinuation patterns and reasons among
chronic lymphocytic leukemia (CLL) patients initiating first-line (1L) and second-line (2L) …

Therapy for chronic lymphocytic leukemia has improved dramatically over the past decade
with the introduction of new targeted therapies and a paradigm shift toward targeted …

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the Western
society with an incidence of over 20,000 new cases per year in the United States. The two …